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ABSTRACT
Atrial fibrillation (AF) is the most common arrhythmia conferring a fivefold increased risk 
of stroke. Stroke prevention is the cornerstone of management of patients with AF. Asians 
have a generally higher incidence of AF-related risks of stroke and bleeding (particularly 
intracranial bleeding), compared with non-Asians. Despite the well-documented efficacy and 
relative safety of oral anticoagulation for stroke prevention among Asians, the suboptimal 
use of oral anticoagulation remains common. The current narrative review aims to provide 
a summary of the available evidence on stroke prevention among patients with AF focused 
on the Asia region, regarding stroke and bleeding risk evaluation, the performance of oral 
anticoagulation, and current use of thromboprophylaxis.
Keywords: Atrial fibrillation; Stroke; Prevention; Anticoagulant agents; Asian continental 
ancestry group
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia with increasing prevalence 
worldwide including in Asia.1) The incidence and prevalence of AF increased with population 
aging.2) By 2050, 2.9 million of people may suffer from AF-associated stroke.3) Overall, 
AF confers a fivefold increased risk of stroke which is more severe compared with those 
of other etiologies.4-7) AF-related stroke often results in up to 20% high-risk of death and 
approximately 60% of disability.8)9)
Stroke prevention, i.e., oral anticoagulation (OAC), is the cornerstone of management for 
patients with AF. Therefore, optimizing stroke prevention for patients with AF in Asia has 
a great impact on the global health burden of this most common arrhythmia.10) Among 
patients with AF, the risk of stroke is not homogeneous and increases with the presence of 
more risk factors for stroke. The more common stroke risk factors include age, heart failure 
(HF), diabetes mellitus, previous stroke/transient ischemic attack (TIA), vascular disease 
and sex category (female gender), have been used to formulate a simple risk stratification 
scheme, the congestive HF, hypertension, age ≥75 (2 points), diabetes mellitus, previous 
stroke/TIA (2 points), vascular disease, age 65–74, sex category (female gender) (CHA2DS2-
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VASc) score, for predicting individual's risk of stroke.11) Performance of this score has been 
well-validated in Asians.
Compared to control or placebo, OAC with vitamin K antagonist (VKA) reduces stroke by 
64% and all-cause mortality by 26%.12) However, VKA use has significant shortcomings, 
such as narrow therapeutic range, multiple foods and drugs interaction and the need for 
monitoring. Further, the performance of VKA is suboptimal in Asians, and is associated 
with a high-risk of intracranial hemorrhage (ICH), frequently related to poor anticoagulation 
control (reflected by poorer time in therapeutic range [TTR]) related to use of herbs and 
dietary habits in Asians.3)13)
Currently, the non-VKA oral anticoagulants (NOACs) have changed the landscape of 
anticoagulation in patients with AF. The improved efficacy, safety and convenience profiles 
of NOACs have encouraged the wide use of this anticoagulant worldwide. Also, NOACs are 
associated with lower risk of bleeding events, especially for ICH, compared with the VKA.14-17) 
The recent development of reversal agents for NOACs make it possible to “switch off ” the 
anticoagulation effects of these agents in some urgent situations, such emergent surgery, 
ICH and other major bleedings. Thus, the multiple benefits of NOAC make them more 
suitable as an OAC choice for Asians. Indeed, a national cohort study from Korea has shown 
that Asians benefit more from NOACs compared with non-Asians.18)
Although the provision of stroke prevention has improved among Asians during the past 
decades, suboptimal OAC use remains common in this region. Multiple factors, including 
a fear of bleeding events, inconvenience of anticoagulation quality check, lower adherence, 
etc. have all been related to the underuse of OAC, which contribute to a high-risk of stroke in 
Asian patients with AF.
The current narrative review aims to provide a summary of the available evidence on stroke 
prevention among patients with AF focused on the Asia region, regarding stroke and 
bleeding risk evaluation, the performance of OAC, and current use of thromboprophylaxis. 
We also provided a flowchart of decision-making process of stroke prevention in patients 
with AF from Asia (Figure 1).
ATRIAL FIBRILLATION-RELATED STROKE IN ASIAN
The prevalence of AF-related stroke has been reported in Asian cohorts from the recent 
randomised trials of the NOACs.14-17) For example, in a subanalysis of the Randomized 
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, the absolute annual rate 
of ischemic stroke was numerically higher in Asians compared with non-Asians (2.05% vs. 
1.14% in dabigatran 110 mg group, 1.12% vs. 0.81% in the dabigatran 150 mg group, and 
2.02% vs. 0.98% in the warfarin group).19) A subanalysis of the Rivaroxaban versus Warfarin 
in Nonvalvular Atrial Fibrillation (ROCKET-AF) trial revealed a higher absolute annual rate 
of ischemic stroke in East Asia (not including Japan) compared with non-East Asia (2.24% 
vs. 1.60% in warfarin group).20) Also, in the Effective Anticoagulation with factor Xa Next 
Generation in Atrial Fibrillation (ENGAGE AF) trial, East Asians had a numerically higher 
annual rate of ischemic stroke compared with non-East Asians (1.31% vs. 0.89% in warfarin 
group).21) Such differences among Asian populations were again confirmed in the Apixaban 
versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE) trial.22)
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STROKE RISK STRATIFICATION IN ASIANS
The CHA2DS2-VASc score is widely used in different populations and got recommended 
by most guidelines regarding stroke risk evaluation in AF.23-26) The CHA2DS2-VASc score 
was derived from Western populations (36 countries from Europe), with good accuracy in 
predicting stroke risk, especially in identifying low-risk patients.11)
Since its original derivation, the CHA2DS2-VASc score has also been validated in Asian 
populations. For example, in a large cohort study enrolled 186,570 Chinese patients with AF, 
the CHA2DS2-VASc score outperformed the older CHADS2 score with a better area under curve 
(AUC) for predicting ischemic stroke (0.698 vs. 0.659, p<0.0001)27). Further, the CHA2DS2-
VASc score showed better capability in identifying low-risk patients. Indeed, in patients with 
a CHADS2 score of 0, the CHA2DS2-VASc score ranged from 0–3 with an annual risk of stroke 
ranging from 1.15% to 4.47%; of note, among patients with a CHA2DS2-VASc score of 0, the 
annual stroke risk was around 1.15%.27)
In a meta-analysis including 6 cohort studies of AF patients from Asia regions, absolute 
event rates were usually lower when patients were categorized as the CHA2DS2-VASc score 
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1 in male
2 in female
0 in male
1 in female
Evaluate other
factors*No OAC
Re-evaluationRe-evaluation
Non-valvular
AF
CHA2DS2-VASc
≥2 in male
or ≥3 in female
Second choice:
VKA
First choice:
NOACs
Increase adherence
Maintain TTR ≥70%Increase adherence
Address modifiable risk factors;
Regular follow-up and education
Re-evaluation
No
YesBleeding risk
evaluation
AF patients
on OAC HAS-BLED ≥3
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC choosing 
and bleeding risk control. Stroke and bleeding risk re-evaluation should be made at each medical contact. 
AF = atrial fibrillation; CHA2DS2-VASc = congestive HF, hypertension, age ≥75 (2 points), diabetes mellitus, previous stroke/TIA (2 points), vascular disease, age 
65–74, sex category (female gender); HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international 
normalized ratio, elderly, drugs/alcohol concomitantly; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; TTR = time in 
therapeutic range; VKA = vitamin K antagonist. 
*Including patients' preference, risk factor severity (such as blood pressure control), bleeding risk.
of 0–1, compared to a CHADS2 score of 0–1.28) This study demonstrated that when compared 
with the CHA2DS2-VASc score, there was a 1.71-fold elevated stroke risk among patients 
stratified as “low-risk” using a CHADS2 score of 0, or a 1.40-fold increased with a CHADS2 
score of 1.28)
The performance of the CHA2DS2-VASc score in identifying truly low-risk AF patients for 
stroke was validated in a Korean Nationwide cohort study (n=5,855).29) The CHA2DS2-VASc 
score had the best sensitivity (98.8% vs. 85.7% in the CHADS2 score and 74.8% in the 
anticoagulation and risk factor in atrial fibrillation [ATRIA] score) and negative predictive 
value (98.8% vs. 95.3% for the CHADS2 score and 93.7% for the ATRIA score) for predicting 
stroke risk during 5 years of follow-up.29) In another Korean Nationwide population-based 
study (n=10,846), the CHA2DS2-VASc score was superior in identifying truly low-risk patients 
compared with the CHADS2 score.30)
The CHA2DS2-VASc score also showed better performance than the ATRIA score, in 
predicting ischemic stroke among AF patients from Taiwan (n=186,570).31) In this study, 
the CHA2DS2-VASc score had higher c-index than the ATRIA score (0.698 vs. 0.627, Delong 
test, p<0.0001) with a significantly improved net reclassification index of 11.7% (p<0.0001). 
Patients stratified as low-risk in the ATRIA score had a CHA2DS2-VASc score ranging from 0 
to 7, and annual stroke rates from 1.06% to 13.33%.31)
Different age threshold for the CHA2DS2-VASc score in Asians?
An age ≥65 was set as the threshold of an increased risk of stroke in the original CHA2DS2-
VASc score in non-Asians. However, such an age threshold may be different in Asians.
In an observational study from Hong Kong, age ≥50 years was associated with a substantial 
stroke risk, with an annual ischemic stroke risk of 5.87% in patients aged 50–65 years.32) 
This result was confirmed in another large Asian nationwide cohort from Taiwan including 
186,570 patients with AF, using a cutoff of 50 years, whereby patients could be further 
stratified into 2 subgroups with different stroke risk (>50 years of age: 1.78%/year vs. <50 
years of age: 0.53%/year).33) Therefore, in this Asian cohort study, age at 50–74 was suggested 
as 1 point in a modified CHA2DS2-VASc score which performed better than the original 
CHA2DS2-VASc score (AUC, 0.71 [0.70–0.71] vs. 0.69 [0.68–0.69], DeLong test p<0.0001), 
with an improved net reclassification index of 3.39% [2.16–4.59%].34) Thus, among Asian 
populations, maybe age ≥50 should be treated as a risk factor and should meet the stroke 
prevention threshold.
Oral anticoagulation for patients with a CHA2DS2-VASc score of 1 in males and 
2 in females from Asia?
For obtaining a net clinical benefit (NCB), the OAC initiation threshold is 1.7% for annual risk 
of stroke using VKAs and 0.9% for the NOACs.1) Indeed, considering the evidence supporting 
NCB, patients with a CHA2DS2-VASc score of 1 in males or 2 in females should receive OAC, 
as is recommended by guidelines.23-26)35)36)
As demonstrated in an Asian study, in patients with only one non-gender stroke risk factor, 
OAC may be associated with positive NCB, considering the high stroke risk in these patients 
(1.96–3.50% in males, 1.91–3.34% in females).31)37) In another study from Taiwan, in patients 
with AF aged 20 to 49 and with a CHA2DS2-VASc score of 1 in males, the risk of ischemic 
stroke was 1.30% (0.94-1.71%) per year; which among those with a CHA2DS2-VASc score of 
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2 in females, this risk was 1.40% (1.11–1.67%).36) For these patients, may be NOAC should be 
considered for stroke prevention considering the treatment threshold of obtaining a positive 
NCB at a 0.9% annual risk of stroke.
In clinical work, a comprehensive consideration of OAC is needed for these patients with 
only one non-major risk factor for stroke. Although the CHA2DS2-VASc score provides 
a viable approach to evaluate individuals' risk of stroke, however, the stroke risk is not 
equal for patients for a particular CHA2DS2-VASc score point. For example, well-controlled 
hypertension may a have lower risk of stroke compared with uncontrolled hypertension. Also, 
age at 74 would confer higher stroke risk than the age at 65. Therefore, the CHA2DS2-VASc 
score should be regarded as a simple and practical score for everyday practice, and clinicians 
still need some degree of individualized decision-making.
Guideline recommendations in Asia
Currently, Asian countries have the 2017 consensus of the Asia Pacific Heart Rhythm 
Society (APHRS) on stroke prevention in AF.24) In the APHRS consensus document, the 
CHA2DS2-VASc score was recommended for the evaluation of stroke risk in Asian patients 
with non-valvular AF. Patients with at least one non-gender stroke risk factor, i.e., CHA2DS2-
VASc score ≥1 in males or ≥2 in females, were recommended for OAC use, and NOACs 
were recommended over VKA.24) In Japan, the 2013 Japan Circulation Society guideline for 
pharmacotherapy of AF recommend the CHADS2 score for risk stratification, and patients 
with CHADS2 score ≥2 should consider NOACs use.38) Also, in this guideline, OAC with 
dabigatran or apixaban should be performed in intermediate-risk patients with a CHADS2 
score of 1 (class I). Anticoagulation therapy with rivaroxaban, edoxaban or warfarin should 
be considered for intermediate-risk patients with a CHADS2 score of 1 (class IIa).38) In the 
2016 guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology 
for the management of AF, CHA2DS2-VASc score was recommended to assess stroke risk 
in nonvalvular AF.39) In patients with a CHA2DS2-VASc score ≥1 (beyond female sex alone), 
antithrombotic therapy should be considered and NOACs were preferred over VKA.39) In the 
2018 Korean Heart Rhythm Society guidelines for stroke prevention therapy, the CHA2DS2-
VASc score was recommended for the assessment of stroke risk.40) NOACs or anticoagulation 
therapy using warfarin should be recommended for antithrombotic therapy when the 
CHA2DS2-VASc score ≥2.41)
A dynamic evaluation of stroke risk
In the real-world, a patient's stroke risk is not static. Increasing age, newly developed 
comorbidities, such as diabetes mellitus, HF or vascular diseases, may increase individual's 
risk of stroke.
In an Asian study including 31,039 patients from Taiwan, the mean baseline CHA2DS2-VASc 
score increased from 1.29 to 2.31 during follow-up.42) Nearly 60% of patients experienced an 
increased CHA2DS2-VASc score. Further, the change in risk (referred to as the ‘delta CHA2DS2-
VASc score’) performed better in evaluating the stroke risk, when compared with baseline or 
follow-up CHA2DS2-VASc scores.42) Therefore, a dynamic evaluation of stroke risk is necessary 
and should be performed at each medical contact.43)
In Korean nationwide population-based study in 2015 (n=276,246), the median age (from 
68 to 71 years) and the prevalence of diabetes mellitus and HF in patients with AF has been 
increased between 2008 and 2015.2) Also, the high-risk population with a CHA2DS2-VASc 
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score of ≥2 increased from 80.2% to 86.8%. The proportion of patient with AF who need to 
be treated with anticoagulation therapy increased significantly due to aging and increasing 
comorbidities (i.e., HF and diabetes mellitus).
Another recent nationwide study from Korea (n=167,262) also demonstrated an increasing 
CHA2DS2-VASc score among patients with AF during 10 years of follow-up. There were 46.6% 
of ‘low-risk’ patients and 72.0% of ‘intermediate-risk’ patients re-classified to higher stroke 
risk categories.43)
BLEEDING RISK ASSESSMENT IN THE ASIAN 
POPULATIONS
It is important to evaluate the risk of bleeding in AF patients taking OAC. Patients with 
high bleeding risk need more regular review and early follow-up (e.g., 4 weeks rather than 
4–6 months), and modifiable bleeding risk factors should be addressed, such as anemia, 
uncontrolled hypertension, alcohol use, and renal dysfunction.44)45) In terms of bleeding risk 
prediction, relying on modifiable bleeding risk factors alone is an inferior strategy compared 
to an established bleeding risk score for risk stratification.46-48)
Several bleeding risk evaluation tools have been proposed in the last decade.49-52) In patients 
with AF from Asia, the hypertension, abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile international normalized ratio (INR), elderly, drugs/alcohol 
concomitantly (HAS-BLED) score was compared with other bleeding risk scoring systems in 
a large cohort study from Taiwan (n=40,450), whereby the HAS-BLED score outperformed 
other scoring systems, including the HEMORR2HAGES score, the ATRIA score and the 
outcomes registry for better informed treatment (ORBIT) score, as evident from the net 
reclassification index.48)
In a large cohort of Chinese inpatients with AF (n=4,824), the HAS-BLED score showed 
good performance in predicting major bleeding events (AUC, 0.72 [0.65–0.79]) and ICH 
(AUC, 0.83 [0.75–0.91]).53) The HAS-BLED score was significantly better in predicting major 
bleeding events and ICH, compared with the ATRIA and the ORBIT scores (Delong test, 
p<0.05, respectively). Additionally, the HAS-BLED score resulted in net reclassification 
improvement of 17.1–65.5% in predicting major bleeding events and 29.5–67.3% in ICH (all 
p<0.05).53)
Considering the dynamic risk of bleeding, a follow-up HAS-BLED score may be more viable 
for evaluating individual bleeding risk. In a “real-world” AF cohort study from Taiwan 
(n=19,566), follow-up HAS-BLED (AUC, 0.63 [0.62–0.64]) and the change in HAS-BLED 
risk (i.e., ‘delta HAS-BLED score’) (AUC, 0.62 [0.61–0.63]) had higher predictive accuracy of 
major bleeding compared with the baseline HAS-BLED score (AUC, 0.54 [0.53–0.55]; Delong 
test, p<0.05 respectively) or simply relying on modifiable bleeding risk factors.54)
In clinical settings, other risk factors may also need consideration for bleeding risk 
evaluation. For example, in Korean patients with AF taking NOACs (n=1,353), underweight 
was found to have an increased risk of major bleeding compared with those with normal 
weight or overweight to obesity.55) Dose reduction in such patients should be considered 
more in Asian to decrease the risk of bleeding.
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EFFECTIVENESS AND SAFETY OF ORAL 
ANTICOAGULATION IN ASIAN POPULATIONS
The efficiency of OAC in reducing stroke and systemic embolism (SE) has been well 
identified. Dose-adjusted VKA reduces stroke/SE by 64% and all-cause mortality by 26%, 
compared with placebo or control.2)3) In patients using VKAs, the TTR >65–70% guarantees 
an optimal OAC quality and need to be maintained. Nevertheless, poor TTR has been 
associated with worse outcomes.56)57)
In the last decade, NOAC has superseded traditional VKAs for stroke prevention in patients 
with nonvalvular AF, given their quick action, less drug and/or food interactions, and lack 
of necessity for anticoagulation monitoring. The four available NOACs, i.e., dabigatran, 
rivaroxaban, apixaban and edoxaban, show good efficacy and safety for stroke prevention in 
AF patients in large randomized trials.14-17) The good performance of NOACs in randomised 
trials has been complemented and augmented by so-called ‘real-world’ evidence from large 
post-marketing observational cohorts.58-60) Importantly, all the NOACs were associated with 
significantly reduced risk (25–82%) for ICH shown in different subgroups of patients.61)62) The 
efficacy and safety of NOACs among Asian populations with AF have also been demonstrated 
in subgroup analysis from the major trials (Table 1).14-17)19-22)63)
In a subanalysis of the RE-LY study, dabigatran had better (150 mg) or similar (110 mg) 
efficacy compared with warfarin (Table 1).19) Also, dabigatran 150 mg was associated with a 
43% reduced major bleeding, 60% reduced ICH, and 40% reduced total bleeding (hazard 
ratio [HR], 0.60 [0.51–0.70]) amongst Asian patients. Dabigatran 110 mg was associated with 
a 43% reduced major bleeding, 80% reduced ICH and 52% reduced total bleeding (HR, 0.48 
[0.40–0.56]).19) Further, dabigatran 150 mg in Asians had a greater NCB compared with non-
Asians (p interaction, 0.004).19)
In the ROCKET-AF trial, 932 patients with AF were enrolled in East Asia.20) Rivaroxaban had a 
similar risk of stroke/SE compared with warfarin (HR, 0.78 [0.44–1.39]).20) Also, rivaroxaban 
had a similar risk of major or nonmajor clinically relevant bleeding risk compared with 
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Table 1. Efficacy and safety of NOACs in Asians from the randomised trials
Study  
(No. of Asians) NOACs
Ischemic stroke Stroke/SE Major bleeding Intracranial hemorrhage All-cause mortality
Risk* HR Risk* HR Risk* HR Risk* HR Risk* HR
RE-LY19)  
(n=2,782)
Dabigatran 
150 mg
1.12%  
vs. 2.02%
0.55  
(0.32–0.95)
1.39%  
vs. 3.06%
0.45  
(0.28–0.72)
2.17%  
vs. 3.82%
0.57  
(0.38–0.84)
0.45%  
vs. 1.10%
0.40  
(0.18–0.92)
4.01%  
vs. 5.09%
0.78  
(0.57–1.07)
Dabigatran 
110 mg
2.05%  
vs. 2.02%
1.01  
(0.63–1.61)
2.50%  
vs. 3.06%
0.81  
(0.54–1.21)
2.22%  
vs. 3.82%
0.57  
(0.39–0.85)
0.23%  
vs. 1.10%
0.20  
(0.07–0.60)
5.01%  
vs. 5.09%
0.98  
(0.73–1.32)
ROCKET-AF20)  
(n=932)
Rivaroxaban 2.12%  
vs. 2.24%
Not given 2.63%  
vs. 3.38%
0.78  
(0.44–1.39)
3.44%  
vs. 5.14%
Not given 0.59%  
vs. 2.46%
0.24  
(0.08–0.71)
2.58%  
vs. 3.57%
0.73  
(0.41–1.27)
J-ROCKET AF64)  
(n=1,278)
Rivaroxaban Not given 0.40  
(0.17–0.96)
1.26%  
vs. 2.61%
0.49  
(0.24–1.00)
3.00%  
vs. 3.59%
0.85  
(0.50–1.43)
0.8%  
vs. 1.6%
Not given Not given Not given
ENGAGE  
AF-TIMI 4821)  
(n=1,943)
Edoxaban 
60 mg
0.80%  
vs. 1.31%
0.64  
(0.31–1.32)
1.34%  
vs. 2.62%
0.53  
(0.31–0.90)
2.86%  
vs. 4.80%
0.61  
(0.41–0.89)
0.60%  
vs. 1.92%
0.31  
(0.15–0.66)
1.73%  
vs. 2.77%
0.63  
(0.40–0.98)
Edoxaban 
30 mg
2.26%  
vs. 1.31%
1.77  
(1.01–3.10)
2.52%  
vs. 2.62%
0.93  
(0.63–1.54)
1.59%  
vs. 4.80%
0.34  
(0.21–0.54)
0.46%  
vs. 1.92%
0.24  
(0.11–0.56)
1.84%  
vs. 2.77%
0.66  
(0.42–1.02)
ARISTOTLE22)  
(n=1,993)
Apixaban 
5 mg
2.22%  
vs. 1.90%
1.17  
(0.74–1.85)
2.52%  
vs. 3.39%
0.74  
(0.50–1.10)
2.02%  
vs. 3.84%
0.53  
(0.35–0.80)
0.67%  
vs. 1.88%
0.36  
(0.18–0.71)
2.86%  
vs. 2.81%
1.02  
(0.70–1.50)
Numbers in bold stands for significance.
ARISTOTLE = Apixaban versus Warfarin in Patients with Atrial Fibrillation; ENGAGE AF-TIMI 48 = Effective Anticoagulation with factor Xa Next Generation in Atrial 
Fibrillation-Thrombolysis In Myocardial Infarction 48; NOAC = non-vitamin K antagonist oral anticoagulant; RCT = randomized controlled trial; HR = hazard ratio; 
J-ROCKET AF = Rivaroxaban vs. Warfarin in Japanese Patients with Atrial Fibrillation; RE-LY = Randomized Evaluation of Long-Term Anticoagulation Therapy; 
ROCKET-AF = Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation; SE = systemic embolism.
*Annual incidence, NOACs vs. warfarin.
warfarin (HR, 1.01 [0.79–1.30]).20) In the Rivaroxaban vs. Warfarin in Japanese Patients with 
Atrial Fibrillation (J-ROCKET AF) trial conducted in Japan (n=1,278), rivaroxaban had similar 
stroke/SE rates compared with warfarin (Table 1), while the risks of major bleeding and 
non-major clinically relevant bleeding (HR, 1.20 [0.92–1.56]) were comparable between the 
rivaroxaban and warfarin groups (Table 1).64)
In a subanalysis of the Effective Anticoagulation with factor Xa Next Generation in Atrial 
Fibrillation-Thrombolysis In Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, 1,943 
patients with AF were recruited from East Asia, including Japan, China, Taiwan and South 
Korea.21) Compared with warfarin, edoxaban 60 mg was associated with a 47% reduced risk of 
stroke/SE21). Edoxaban 30 mg had a similar risk of stroke/SE compared with warfarin. The risk 
of major bleeding was significantly reduced by edoxaban (39% in edoxaban 60 mg and 66% 
in edoxaban 30 mg) compared with warfarin (Table 1).21)
In the ARISTOTLE trial, 1,993 patients with AF were from East Asia. Apixaban 5 mg had 
a similar risk of stroke/SE in East Asians and a 47% significantly reduced risk of major 
bleeding.22) In addition, a 29% reduced risk of major bleeding or clinical relevant nonmajor 
bleeding with was observed in apixaban treated group.22)
These trial data are supported by real-world studies. In a real-world study from the Korean 
National Health Insurance Service database (n=34,833), NOACs (n=11,611) had similar risk 
of ischemic stroke (HR, 0.98 [0.78–1.22]) and lower risk of ICH (HR, 0.50 [0.36–0.68]) 
compared with warfarin. All-cause mortality was significantly lower in patients taking 
dabigatran (HR, 0.52 [0.39–0.68]) or apixaban (HR, 0.32 [0.18–0.53]).18)
The comparison of the performance of NOACs in Asians and non-Asians was also reported in 
a recent meta-analysis using aggregate data from phase III clinical trials.65) When compared 
with VKAs, standard-dose NOACs reduced stroke/SE more in Asians than in non-Asians 
(odds ratio [OR], 0.65 [0.52–0.83] vs. 0.85 [0.77–0.93]; p interaction, 0.045). Standard 
NOACs were also associated with a 20% reduced all-cause mortality compared with VKAs in 
Asians (OR, 0.80 [0.65–0.98]).65) Also, standard-dose NOACs had lower major bleeding (OR, 
0.57 [0.44–0.74] vs. 0.89 [0.76–1.04]; p interaction, 0.004) and hemorrhagic stroke (OR, 0.32 
[0.19–0.52] vs. 0.56[0.44–0.70]; p interaction, 0.046). An increased risk of GI bleeding was 
only observed in non-Asians (OR, 1.44 [1.12–1.85]) but not in Asians (OR, 0.79 [0.48–1.32]) (p 
interaction, 0.041).65)
In a retrospective Japan cohort study with propensity-matched comparison (n=11,972 for 
patients on apixaban and warfarin, respectively), apixaban was associated with significantly 
lower risk of any bleeding (HR, 0.81 [0.73–0.90]), major bleeding (HR, 0.66 [0.51–0.85]) and 
stroke/SE (HR, 0.64 [0.48–0.85]) compared with warfarin.66)
In a recent study, including 1,834 patients with non-valvular AF from Korea, dabigatran had 
similar efficacy in reducing stroke/SE. Dabigatran 110 mg was associated with lower risk of 
major bleeding (HR, 0.19 [0.07–0.55]). In this study, the number of patients in dabigatran 
150 mg was 294 compared with 550 in dabigatran 110 mg group and 990 in warfarin group, 
which may undermine the safety profile of dabigatran 150 mg.67)
Recently, in a randomized, multicenter study from Korea (n=183), the efficacy and safety 
of rivaroxaban were compared with warfarin among patients experienced recent mild AF-
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related stroke within the previous 5 days. During 4 weeks of follow-up, rivaroxaban showed 
no differences in primary endpoint (composite of new ischemic lesion or new ICH seen on 
results of magnetic resonance imaging) (relative risk [RR], 0.91 [0.69–1.20]) and new ICH 
(RR, 1.10 [0.70–1.71]) compared with warfarin.68)
In the real-world setting, choosing the standard or low-dose of NOACs is highly subjective 
at the level of clinician.69) In the SAKURA AF registry (n=3,266), 20–30% of NOAC users 
received an inappropriate reduced dose of NOAC.70) However, a reduced dose of NOACs 
should not be encouraged for general patients. In a meta-analysis of 3,155 Asian patients 
enrolled from the RE-LY and ENGAGE AF trials, standard-dose NOACs were associated 
with significantly reduced risk of stroke/SE and ischemic stroke compared with low-dose 
NOACs (RR, 0.62 [0.45–0.85] for stroke/SE; RR, 0.55 [0.38–0.79] for ischemic stroke); 
however, rates of major bleeding (RR, 1.31 [0.74–2.33]), ICH (RR, 1.54 [0.72–3.30]), and 
life-threatening bleeding (RR, 1.49 [0.87–2.55]) with the two dosing regimens were similar.71) 
Also, only certain clinical risk criteria justify dose reduction.
LEFT ATRIAL APPENDAGE OCCLUSION IN ASIAN 
POPULATIONS
Left atrial appendage (LAA) has been considered as the major site of clot formation in AF. 
Occlusion of the LAA was therefore suggested to reduce stroke risk in patients with non-
valvular AF.
In the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with 
Atrial Fibrillation (PROTECT-AF) study, the annual primary efficacy event (stroke/SE and 
cardiovascular death) rate was 3.0% in the left atrial appendage occlusion (LAAO) group 
(n=463) and 4.9% in the warfarin group (n=244) (RR, 0.62 [0.35–1.25]), the annual primary 
safety endpoint (major bleeding, pericardial effusion, and device embolization) rate was 
higher in the LAAO group compared with warfarin group (7.4 per 100 patient-years vs. 4.4 per 
100 patient-years; RR, 1.69 [1.01–3.19]).72) In the WATCHMAN Left Atrial Appendage Closure 
Device in Patients with Atrial Fibrillation vs. Long-term Warfarin Therapy (PREVAIL) study, 
LAAO was non-inferior to warfarin for ischemic stroke prevention or SE during 18 months 
of follow-up. The rate of composite of stroke, SE and cardiovascular/unexplained death was 
6.4% in the LAAO group vs. 6.3% in the control group (RR, 1.07 [0.57–1.89]).73)
In a patient-level meta-analysis of 5-year outcomes from the PROTECT-AF and PREVAIL 
studies, LAAO (n=732) was associated with a non-significant increased risk of ischemic 
stroke/SE (HR, 1.71 [0.94–3.11]), compared with warfarin (n=382). Disabling stroke was lower 
in the LAAO group (HR, 0.45 [0.21–0.94]). The risk of hemorrhagic stroke was significantly 
lower in the LAAO group (HR, 0.20 [0.07–0.56]); however, the risks of all-cause major 
bleeding (including procedure-related) were comparable in the LAAO group and the warfarin 
group (HR, 0.91 [0.64–1.29]).74)
Currently, there is limited evidence regarding the effectiveness and safety of LAAO in Asians. 
Previously, a small size report (n=20) showed that the success rate of LAAO was 95% at two 
Asian centers.75) In this study, one procedure was abandoned because of catheter-related 
thrombus formation, while one patient experienced coronary artery air embolism. No stroke 
or death occurred at a mean follow-up of 12.7 months.75)
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In a recent registry of patients with AF from Korea (n=142), including 10 patients with and 
132 without LAA thrombus, LAAO was performed in multicenter facilities between 2010 to 
2016. In this study, 6 patients experienced periprocedural complications. During the mean 
23.2±17.5-month follow-up, 7 major adverse cardiac events occurred (1 cardiovascular death, 
6 ischemic strokes).76) Another multicenter study in Korea (n=96) demonstrated that during 
21.9-month follow-up after LAAO, the incidence of death, stroke, and major bleeding was 
5.2%, 4.2%, and 1.0%, respectively.77) On transesophageal echocardiography of 93 patients 
within 6 months after the procedure, 24 residual leaks were observed (25.8%; 2 mild, 18 
moderate, and 4 major).77)
Another single center study from from China included 122 AF patients with CHA2DS2-VASc 
score ≥1 for LAAO using WATCHMAN device.78) The mean CHA2DS2-VASc score were 4.09 in 
the primary prevention group and 1.93 in secondary prevention group. The success rate of 
the procedure was 98.5–100% with a low complication rate (not given). Stroke rates were low 
in the primary (1.47%) and secondary prevention groups (2.13%).78)
The safety of LAAO procedures is always a major concern. In the PROTECT-AF study, 
procedural-related adverse events at 7 days after the procedure occurred in 8.7% of 
patients, including pericardial tamponade requiring intervention in 4.0%.72) In the 
Amulet Global Observational Registry (n=1,088), 3.2% of patients experienced major 
procedural complications, including 1.2% pericardial effusion or tamponade, 0.9% vascular 
complications, 0.2% periprocedural stroke and 0.2% death.79) However, device-related 
complications may reduce with accumulating operator experience.
When choosing LAAO for patients with AF, the most driven factor would generally be the fear 
of ICH or reoccurrence of major bleeding. Nevertheless, the NOACs showed a significantly 
decreased risk of ICH and major bleeding, which may compromise the supporting evidence 
of choosing LAAO rather than OACs in the general patient with AF. In addition, LAAO 
cannot eliminate the need for antithrombotic therapy, including a period of peri-procedural 
anticoagulation and long-term antiplatelet therapy, which is probably no safer than NOACs. 
Further, LAAO would only aim at reducing the thrombin formation at LAA and has no 
influence on other clot origins in AF. Also, LAAO induced left atrium size increasing and left 
ventricular filling pressure need further study.80)
Therefore, LAAO should only be considered in patients with clear absolute contra-indications 
for long-term OAC.23)24) Also, the performance of LAAO should be compared with NOACs, 
considering the later showed significant benefits over warfarin.
CURRENT SITUATION OF ORAL ANTICOAGULATION USE 
IN ASIA
Over the last decade, in Asia-Pacific countries, the utilization rate of VKA has been around 
15–20%.81) Such situation has improved recently, with the introduction of NOACs. In the 
Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial 
Fibrillation (GLORIA-AF) registry reported at 2015, OAC use was seen in 57.4% of patients 
with AF with ≥1 stroke risk factors, including 31.9% on VKAs and 25.5% on NOACs.82) The 
total OAC use was lower in Asia (55.2%) compared to in Europe (90.1%).83) Amongst those 
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taking OAC, NOACs were used in about 50.2% of patients in Asia, although still lower than 
other regions, such as North America 66.5%.83)
There are regional differences in OAC use in Asia. In the last decade from 2001 to 2012, 
in an observational study (n=921) of a relatively rural area, Yunnan Province of southwest 
China, less than 10% of patients with AF received VKA treatment, which has increased from 
0.0% at 2007 to 9.5% at 2012.84) During 2011 to 2014, in Beijing, China, a survey involving 32 
hospitals and 7,977 AF patients demonstrated OAC use of 36.5% among those with CHA2DS2-
VASc score ≥2, which was increased from 30.2% at 2011 to 57.7% at 2014.85) In a “real-world” 
observational study from Hong Kong (n=9,727) at 2014, only 19.7% were taking warfarin.86) 
Also, in the same area, among the elderly patients with AF using the same database (≥80 
years, n=2,339), there was only 23.8% received warfarin treatment.81)
A trend study in Korea between 2000 to 2013 showed that 86.1% of patients with AF had 
CHA2DS2-VASc score ≥2, however, only 39.1% of these patients were taking warfarin.87) In a 
recent national study of patients with AF from Korea (n=276,246), using the National Health 
Insurance Service database between 2008 to 2015, most of the patients had CHA2DS2-VASc 
score ≥2 (78.2% in 2008 and 83.2% in 2015).88) In the whole study population, OAC use 
increased from 34.7% to 50.6% and NOAC use accounted for 50% of total OAC use.88) In a 
cross-sectional analysis of Korean adults using the 2015 National Health Insurance Service 
database (n=41,505,679), OAC utilization among AF patients was lower in the suburban/rural 
regions compared with that observed in the urban regions (48.2% vs. 51.8%, p<0.001).89) 
Furthermore, the AF prevalence and income levels showed a J-shaped curve, whereas 
NOAC tended to be more commonly prescribed in those with higher income groups. In the 
Comparison study of Drugs for symptom control and complication prEvention of Atrial 
Fibrillation (CODE-AF) Registry, 6,275 patients with nonvalvular AF were consecutively 
enrolled between 2016 to 2017 from 10 tertiary hospitals in Korea.90) The mean CHA2DS2-
VASc score was 2.7±1.7. OAC was used in 70.1% of patients. Among patients with high stroke 
risk, OAC rate was 82.7%.90)
OAC use has improved in Japan over the last decade. In the study using Shinken Database, 
OAC use increased from 40.7% at 2004 to 55.9% at 2012. Among patients with CHADS2 
score ≥2, OAC use rate was 64.4% during 2010 to 2012. The use of NOAC also significantly 
increased, with nearly 60% of anticoagulated patients treated with NOACs at 2010–2012.91) In 
a recent study from Japan, the Registry of Japanese Patients with Atrial Fibrillation Focused 
on anticoagulant therapy in New Era (RAFFINE) registry study, including 3,901 patients with 
AF from 4 university hospitals and 50 general hospitals/clinics from 2013 to 2015, 87.6% of 
patients received OAC therapy, including 44.6% treated with warfarin, and 43.0% treated 
with NOACs.92)
TTR CONTROL IN ASIANS ON VITAMIN K ANTAGONISTS
Apart from the rate of OAC use, quality of anticoagulation is important for stroke prevention. 
The TTR is an essential measurement for anticoagulation quality of VKA.93) Effective 
anticoagulation when using VKA means TTR ≥65–70%. But TTR can be influenced by 
multiple factors, which have been summarized as the sex, age, medical history, treatment, 
tobacco use, race risk (SAMe-TT2R2) score.4) A patient on VKA with SAMe-TT2R2 score >2 
tends to have suboptimal TTR, who may need more frequent INR checks and monitoring or 
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a switch to NOAC. Non-Westerns, including Asians, have at least 1 point in the SAMe-TT2R2 
score, and tend to have poorer TTR.94-96) The SAMe-TT2R2 score has been validated in Asian 
cohorts97) and was recommended by the APHRS guidelines.24)
Indeed, in a subanalysis of the ENGAGE AF-TIMI 48 trial (n=21,105), the mean TTR was 
also low (56%) in patients from East Asia, including China, Korea, and Taiwan.63) In a 
multicenter retrospective observational study in Korea, including 1,230 patients with AF 
from 16 Korean centers, the mean TTR was 49.1%. None of the 16 centers achieved a mean 
TTR >60%.98) In Thailand, the mean TTR ranged from 40.1% to 62.7% in a cohort study with 
433 AF patients.99) In Malaysia, during a 6 months follow-up with 184 AF patients, the TTR 
was 65.1% in a professional anticoagulation clinic and 48.3% amongst a ‘general’ medical 
clinic.100) In Singapore, the mean TTR of AF patients on warfarin was also poor (58%).101)
A low TTR in Asians may explain the suboptimal anticoagulation efficacy of VKAs. Indeed, 
in a study included 1,034 AF patients in China, warfarin did not show better efficacy in 
stroke prevention compared with aspirin. On the other hand, because of the relatively higher 
baseline risk of ICH102) and lower TTR in Asians, the benefits of VKA in Asia were likely to 
be compromised. However, NOACs were associated with better NCB compared with VKA 
among Asians.103)
A high rate of aspirin uses in Asia
The sole use of aspirin is highly prevalent in many patients with AF is Asia.103)104) As is shown 
in phase I of the GLORIA-AF registry, 49.6% of Chinese AF patients received aspirin alone,105) 
which has decreased to 25.8% at 2015.82) In the Registry on cardiac rhythm disORDers 
(RecordAF-AP) from eight Asian-Pacific countries, aspirin use was more common than VKAs 
use (56–66% vs. 35–47%).106) A large cohort study from Taiwan between 2001–2008 also 
demonstrated a high rate of aspirin use (62%).107) Also, in Hong Kong, a recent real-world 
data showed that 61% of patients received aspirin alone.108) In Korea, the use of aspirin was 
high, despite consistently decreased from 48.2% to 31.5%.88)
BARRIERS TO OPTIMISING ANTICOAGULATION USE IN ASIA
Elderly age is a common reason for low OAC use. In a study from China, age ≥75 years was 
associated with a 74% lower rate of OAC use in patients with AF103); however, a large cohort 
study (n=25,722) in an Asian population demonstrated that among AF patients age ≥90 years, 
warfarin was associated with a lower risk of ischemic stroke (HR, 0.69 [0.49–0.96]) and a 
positive NCB. Further, NOACs were associated with even lower risk of ICH (HR, 0.32 [0.10–
0.97]) without difference in ischaemic stroke risk compared to warfarin.109) In a large real-
world study using the Korean National Health Insurance Service database, among patients 
age ≥75 years, NOACs were associated with similar ischemic stroke (HR, 1.10 [0.80–1.49]) but 
reduced risk of ICH (HR, 0.63 [0.40–0.95]) and all-cause mortality (HR, 0.72 [0.59–0.86]) 
compared with VKA.18)
A recent meta-regression analysis included 26 studies, exploring the effectiveness and safety 
of OAC in older patients (≥65 years). Warfarin use was superior to no antithrombotic therapy 
(RR, 0.59 [0.51–0.76]) and aspirin (RR, 0.44 [0.24–0.64]) for stroke/SE prevention.110) 
NOACs were superior to warfarin for stroke/SE prevention (HR, 0.81 [0.73–0.89]) and were 
associated with lower risk of major bleeding (HR, 0.87 [0.77–0.97]).110)
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Many clinicians may have a misunderstanding that aspirin can reduce stroke in AF and often 
underestimated the risk of bleeding related to aspirin. One study from Japan demonstrated 
the futility of aspirin in reducing stroke risk among low-risk patients.111) In another study from 
Hong Kong, aspirin showed a non-significant reduction in ischemic strokes, compared with 
no therapy.86)
Asian populations were associated with higher risk of ICH compared with the Western 
populations on VKA, which may also related to a low rate of VKA use.3)112) However, such 
situation could be avoided by using NOACs, which were associated with significantly lower 
risk of ICH (up to 80%).62) Finally, the inconvenience of INR checks in patients taking VKA 
and lack of anticoagulation clinics may also induce a high rate of aspirin use in Asia. Low 
persistence and adherence to VKA therapy have been associated with poor outcomes.113)114)
CONCLUSION
Stroke prevention in Asian patients with AF has many challenges, yet opportunities for 
improved care are evident. In many countries, OAC use is suboptimal, with high rates of 
aspirin or non-treatment, and where VKAs are used TTR is poorly managed.115) The NOACs 
offer an opportunity to improve efforts for stroke prevention, and modelling projections 
indicate this would have a major impact in reducing stroke and death, with substantial 
healthcare benefits.116) We should also be aware of the need for a holistic and integrated 
approach to managing the ‘whole’ AF patient, which should be ‘… as simple as ABC’, that is, 
Avoid stroke with Anticoagulation, Better symptom management with decisions on rate or 
rhythm control, and Cardiovascular and comorbidity risk management.117)118) This is relevant 
since AF independently increases all-cause mortality and strokes only account for 1 in 10 
deaths related to AF, while 7 in 10 deaths are cardiovascular.119)120)
Priorities should be to identify the non-treated eligible for stroke prevention, finding those 
on aspirin and treating them with OAC, and finally identifying those on VKA with poor TTR, 
and to swop them to NOACs.
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